Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5168MR)

This product GTTS-WQ5168MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets Canlupfam IL31 gene. The antibody can be applied in Canine atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001165914.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100302725
UniProt ID Q9N0W9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5168MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13688MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ5755MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ1797MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ10326MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ14922MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ4859MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ5659MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ4754MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BPS-804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW